Parsortix system pivotal in novel cancer treatment trial

Published 01/24/2025, 05:06 AM

LONDON - ANGLE plc, a leading liquid biopsy company, has announced a significant development in cancer treatment strategy, utilizing its Parsortix system in a Phase 1 clinical trial. The trial, conducted by Professor Nicola Aceto's team at ETH Zurich and published in Nature Medicine, used the Parsortix system to identify metastatic breast cancer patients with circulating tumor cell (CTC) clusters for targeted treatment with the drug digoxin.

The Parsortix system's ability to isolate CTC clusters from blood samples was instrumental in selecting patients for the trial, which aimed to dissociate these clusters known to significantly increase metastatic potential. The primary endpoint was met, with a notable reduction in CTC cluster size observed in patients treated with digoxin, a repurposed FDA-approved drug.

This groundbreaking study suggests a new direction for cancer treatment, focusing on preventing or suppressing metastasis, which is responsible for the majority of cancer-related deaths. While the trial did not assess clinical outcomes, it provides evidence supporting the development of treatments targeting the metastatic process.

The Parsortix system, already established in the Aceto Lab, is anticipated to be crucial in the pre-clinical and clinical development of novel compounds designed to disrupt CTC clusters. These efforts are further supported by PAGE Therapeutics, co-founded by Professor Aceto, which aims to develop drugs targeting metastatic spread.

CTC clusters, which are more resistant to cancer drugs and can evade the immune system, pose a significant challenge in treating metastatic cancer. The Parsortix system's patented technology allows for the isolation of these clusters, providing a unique approach to advancing cancer treatment.

Professor Aceto highlighted the uncharted opportunity for targeted agents that disrupt metastatic causes, while ANGLE's Chief Scientific Officer, Karen Miller, expressed optimism about the Parsortix system's role in reducing metastatic disease burden and improving patient outcomes.

This research represents a promising step toward a new class of drugs that could profoundly improve treatment success and patient survival across all solid tumors. The information for this article is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.